CSBR (Champions Oncology, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CSBR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-30 | Robert Lawrence Brainin | CEO | A | — | — |
| 2026-01-30 | Robert Lawrence Brainin | Director | A | — | — |
| 2025-11-07 | JOEL ACKERMAN | Director | A | — | — |
| 2025-11-07 | SCOTT R TOBIN | Director | A | — | — |
| 2025-11-07 | Philip P. Breitfeld | Director | A | — | — |
| 2025-11-07 | Daniel Newman Mendelson | Director | A | — | — |
| 2025-11-07 | DAVID SIDRANSKY | Director | A | — | — |
| 2025-11-06 | JOEL ACKERMAN | Director | M | — | — |
| 2025-04-02 | Philip P. Breitfeld | Director | J | — | — |
| 2024-11-18 | DAVID SIDRANSKY | Director | A | — | — |
| 2024-11-18 | JOEL ACKERMAN | Director | A | — | — |
| 2024-11-18 | Daniel Newman Mendelson | Director | A | — | — |
| 2024-11-18 | SCOTT R TOBIN | Director | A | — | — |
| 2024-11-18 | Philip P. Breitfeld | Director | A | — | — |
| 2024-11-01 | JOEL ACKERMAN | Director | M | — | — |
| 2024-04-01 | Brady Davis | President | A | — | — |
| 2024-01-16 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2024-01-12 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2024-01-11 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2024-01-10 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2024-01-09 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2024-01-08 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2024-01-08 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2024-01-05 | JOEL ACKERMAN | Director | M | — | — |
| 2024-01-04 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-12-26 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-12-21 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-12-20 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-11-07 | Philip P. Breitfeld | Director | A | — | — |
| 2023-11-07 | SCOTT R TOBIN | Director | A | — | — |
| 2023-11-07 | DAVID SIDRANSKY | Director | A | — | — |
| 2023-11-07 | Daniel Newman Mendelson | Director | A | — | — |
| 2023-11-07 | JOEL ACKERMAN | Director | A | — | — |
| 2023-10-16 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-10-16 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-10-16 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-10-13 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-10-11 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-10-10 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-10-06 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-10-04 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-10-04 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-09-27 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-09-25 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-09-25 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-09-25 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-09-25 | Daniel Newman Mendelson | Director | Buy | — | — |
| 2023-08-17 | Daniel Newman Mendelson | Director | A | — | — |
| 2023-08-17 | JOEL ACKERMAN | Director | A | — | — |
| 2023-08-17 | Philip P. Breitfeld | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,421,673 | — |
| — | 10%+ Owner | 2,011,882 | — |
| — | 10%+ Owner | 1,713,720 | — |
| — | Director | 1,056,539 | — |
| — | CEO | 858,878 | — |
| — | Director | 770,605 | — |
| — | Director | 198,625 | — |
| — | Director | 80,147 | — |
| — | Director | 30,000 | — |
| — | Director | 5,717 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CSBR quote page; the site-wide leaderboard is on the insider transactions hub.